Saturday 7 November 2026 Export EYPT’s income statement to Excel — free account

EyePoint, Inc.

EYPT Healthcare Biotechnology

EyePoint, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $31.4 million, down 27.5% from fiscal 2024.

Revenue: −90.5%
EPS: −28.2%
Free cash flow: +0.41%

Quarter to June 2026, against a year earlier

Insider buying

0.36 0.00 0.00%

Follow EYPT

Alert me

Market cap: $30.7M
P/E: 0.0×
Fwd P/E: −0.1×
Dividend yield: —
F-score: 3/9
Altman Z: 8.46
Beneish M: −2.16
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Bought, $m 0.07

Sold, $m 2.00

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	1	—	—	—	—	1	—	—	—
Sell	2	1	1	1	1	—	1	—	—	—	—	—

Insider Ownership 6.74%

Capital & Financial Ratios $m

Size

Market Cap 30.68

Revenue ttm 2.79

Net income ttm (306.64)

Free cash flow ttm (271.12)

Net debt Q (180.47)

Valuation

P/E 0.00

Forward P/E (0.10)

Price / sales 11.17

Forward P/S Powerpack

Price / FCF 0.00

Price / book 0.19

Financial health

Current ratio Q 4.50

Debt / equity Q 0.00

Interest coverage Q (8.06)

Growth

Revenue growth Q −90.49%

Operating income growth Q −56.49%

EPS, this year −14.57%

EPS, next year A +41.22%

Revenue, next year A −94.57%

EPS, past 5 yrs —

EPS, next 5 yrs A +27.67%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 53.04%

10-year low 10-year high

P/B against its own 10 years 0.15%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	331	371	306	180
Receivables	1	1	1	0
Inventory	4	2	2	2
Other	—	—	—	—
	345	383	329	189

	2023	2024	2025	Q'26
Payables	7	12	10	17
ST’ Debt	—	—	—	—
Other	—	—	—	—
	63	49	37	42

Compound Annual Growth %

	10y	5y	3y
Sales	15.32%	(1.85%)	(8.83%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	36.80%	75.21%	47.00%

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.92 Actual −1.09

−1.14 −1.03 −0.93 −0.83 −0.72

Q3 FY25 Miss −0.08

Q4 FY25 Miss −0.03

Q1 FY26 Miss −0.20

Q2 FY26 Miss −0.17

Q3 FY26 — Nov 4

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Q3 FY25	−0.77	−0.85	Miss by 0.08
Q4 FY25	−0.78	−0.81	Miss by 0.03
Q1 FY26	−0.79	−0.99	Miss by 0.20
Q2 FY26	−0.92	−1.09	Miss by 0.17
Q3 FY26	−0.88	—	Reports 4 November 2026

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.99)	(1.09)	—	—	—
’25	(0.65)	(0.85)	(0.85)	(0.81)	(3.17)
’24	(0.55)	(0.58)	(0.54)	(0.64)	(2.32)
’23	(0.56)	(0.61)	(0.33)	(0.33)	(1.82)
’22	(0.56)	(0.52)	(0.49)	(1.16)	(2.74)
’21	(0.50)	(0.35)	(0.58)	(0.59)	(2.03)
’20	(1.10)	(1.00)	(0.30)	(1.07)	(3.54)

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	1	1	—	—	—
’25	24	5	1	1	31
’24	12	9	11	12	43
’23	8	9	15	14	46
’22	9	12	10	11	41
’21	7	9	9	12	37
’20	7	4	16	7	34

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(81)	(62)	—	—	—
’25	(53)	(63)	(59)	(65)	(240)
’24	(31)	(20)	(39)	(36)	(126)
’23	(17)	57	(15)	(23)	2
’22	(20)	(19)	(13)	(13)	(65)
’21	(15)	(11)	(8)	(17)	(50)
’20	(16)	(5)	1	6	(14)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(82)	(64)	—	—	—
’25	(53)	(64)	(60)	(66)	(243)
’24	(32)	(21)	(41)	(36)	(130)
’23	(17)	57	(17)	(24)	(2)
’22	(20)	(19)	(14)	(13)	(67)
’21	(15)	(11)	(8)	(17)	(50)
’20	(16)	(5)	1	6	(15)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Jun ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	2	8	6	20	34	37	41	46	43	31	3		+39.0%	2	4	113	+53.4%
	Gross margin, %	0.00	89.19	0.00	86.81	83.09	77.86	79.89	89.93	91.42	93.41	41.75		+93.4 pt	Powerpack EyePoint, Inc.’s next three years, line by line Analysts expect revenue to grow 53.4% a year to 2028 — faster than the 39.0% of the last 9 years. See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	(22)	(18)	(89)	(57)	(45)	(58)	(102)	(71)	(131)	(232)	(307)		+30.0%
	EBT margin, %	(1,349.44)	(245.19)	(1,527.32)	(278.88)	(131.82)	(158.14)	(246.97)	(153.66)	(302.22)	(738.53)	(10,993.79)		+610.9 pt
	Net income	(22)	(18)	0	(57)	(45)	(58)	(102)	(71)	(131)	(232)	(307)		+30.2%
Per share, $
Per share, $	Revenue	0.51	2.13	0.69	1.95	2.68	1.28	1.11	1.18	0.77	0.43	0.03		(2.0%)
	Earnings	(6.80)	(5.20)	(10.50)	(5.40)	(3.54)	(2.03)	(2.74)	(1.82)	(2.32)	(3.17)	(3.74)		(8.1%)
	Cash flow	(5.16)	(5.80)	(2.66)	(5.44)	(1.12)	(1.74)	(1.74)	0.05	(2.24)	(3.28)	(3.09)		(4.9%)
	Capex	0.00	0.00	0.00	(0.02)	(0.03)	(0.01)	(0.06)	(0.09)	(0.07)	(0.04)	(0.04)		n/m
	Free cash flow	(5.16)	(5.80)	(2.66)	(5.46)	(1.15)	(1.75)	(1.80)	(0.04)	(2.31)	(3.32)	(3.13)		(4.8%)
	Book value	6.60	3.77	4.42	0.80	1.44	6.41	2.58	6.85	5.98	4.18	1.92		(5.0%)
	Shares, m	3	4	9	10	13	29	37	39	56	73	79		+41.8%
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		0.0
	P/S	8.52	6.27	46.40	7.94	2.45	9.53	3.29	19.04	9.69	42.66	11.17		15.6
	P/B	4.10	4.99	3.78	19.41	4.56	1.91	1.41	3.29	1.25	4.37	0.19		4.9
	EV/Sales	6.05	4.64	37.37	9.19	2.27	4.81	0.76	12.60	1.92	34.01	(41.12)		11.4
	EV/FCF	(1.61)	(1.14)	(4.10)	(3.29)	(5.29)	(3.52)	(0.47)	(360.53)	(0.64)	(4.39)	0.42		(38.5)
Cash, $m
Cash, $m	Operating cash flow	(16)	(20)	(23)	(57)	(14)	(50)	(65)	2	(126)	(240)	(267)		+34.8%
	Capex	0	0	0	0	0	0	(2)	(3)	(4)	(3)	(4)		+44.6%
	Free cash flow	(16)	(20)	(23)	(57)	(15)	(50)	(67)	(2)	(130)	(243)	(271)		+35.0%
Balance, $m
Balance, $m	Working capital	25	12	26	30	48	214	138	282	334	292	147		+31.5%
	Net debt	(29)	(17)	(28)	25	(6)	(174)	(105)	(331)	(371)	(306)	(180)		+29.9%
	Shareholders’ equity	21	13	38	8	19	184	96	266	337	306	166		+34.8%
Returns, %
Returns, %	ROA	(68.15)	(98.97)	(119.38)	(75.15)	(55.13)	(32.90)	(46.09)	(26.44)	(33.83)	(59.29)	(115.86)		+8.9 pt
	ROIC	0.00	0.00	0.00	(88.45)	(189.54)	(339.83)	0.00	0.00	0.00	(563,504.63)	0.00		(563,504.6) pt
	ROE	(103.19)	(138.61)	(362.69)	(247.12)	(337.87)	(57.58)	(72.84)	(39.04)	(43.42)	(72.19)	(148.70)		+31.0 pt
People
People	Employees	20	22	44	84	101	123	144	121	165	214	—		+30.1%
	Revenue/emp, $m	0.00	0.00	0.00	0.24	0.34	0.30	0.29	0.38	0.26	0.15	—		n/m

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
NNVC NanoViricides, Inc.	$32.9M	— (loss-making)	—	—	n/m	−23.94% (below 0%: shrinking)	0.00%	0.00%	Compare
PMN Promis Neurosciences	$32.7M	— (loss-making)	—	0.00%	n/m	−169.46% (below 0%: shrinking)	0.00%	0.00%	Compare
INMB INmune Bio, Inc.	$32.6M	— (loss-making)	— (loss-making)	+8.70% (above 0%: growing)	n/m	+55.39% (above 0%: growing)	100.00%	0.00%	Compare
EYPT EyePoint, Inc.	$30.7M	— (loss-making)	— (loss-making)	−90.49% (below 0%: shrinking)	n/m	+0.41% (above 0%: growing)	100.00%	(19,207.10%)
IRLA IRulya Therapeutics Inc.	$29.8M	— (loss-making)	—	—	n/m	−63.65% (below 0%: shrinking)	0.00%	0.00%	Compare
LITS Lite Strategy, Inc.	$29.6M	— (loss-making)	— (loss-making)	+647.96% (above 0%: growing)	n/m	+179.28% (above 0%: growing)	0.00%	0.00%	Compare
EDSA Edesa Biotech, Inc.	$28.8M	— (loss-making)	— (loss-making)	−99.88% (below 0%: shrinking)	n/m	−81.24% (below 0%: shrinking)	0.00%	0.00%	Compare
ANVS Annovis Bio, Inc.	$28.6M	— (loss-making)	—	—	n/m	−329.18% (below 0%: shrinking)	—	0.00%	Compare
BCTX BRIACELL THERAP	$28.6M	— (loss-making)	—	—	n/m	+26.73% (above 0%: growing)	0.00%	0.00%	Compare
Median of peers	$29.7M	—	—	+4.35%	—	−43.79%	0.00%	0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 27 April 2026

Chief executive’s pay

Year	Total pay	Actually paid	$100 invested
2025	5.57m	13.99m	522.00

Ownership

Directors and executive officers, together 5.13%

Cormorant Asset Management, LP 9.86%

Suvretta Capital Management 5.70%

Adage Capital Management, L.P. 5.61%

Federated Hermes, Inc. 5.49%

Blackrock, Inc. 5.35%

Paradigm BioCapital Advisors LP 5.00%

Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

EyePoint, Inc. (EYPT) Latest News

28 Oct

Impact 3 · 9:00 AM · Zacks

EyePoint (EYPT) Expected to Beat Earnings Estimates: Should You Buy?

20 Oct

Impact 4 · 10:15 PM · Simply Wall St.

EyePoint (EYPT) Stock Sees Fair Value Cut After Duravyu Trial Setbacks

Impact 4 · 7:37 AM · pharmaceutical-technology.com

EyePoint halves workforce and ends Phase III trial early after endpoint miss

19 Oct

Impact 4 · 4:58 PM · Barchart

EYPT Stock Layoffs: What to Know About the Latest EyePoint Job Cuts

Impact 4 · 9:58 AM · Investing.com

EyePoint crashes as pivotal wet AMD trial fails, prompting 53% workforce cut

Impact 4 · 8:47 AM · InvestorsHub

EyePoint Announces 53% Workforce Reduction Following Phase 3 DURAVYU Trial Results

Impact 4 · 8:08 AM · MT Newswires

EyePoint Pharmaceuticals to Cut 53% of Workforce After Eye Disease Drug Trial Setback

Impact 4 · 7:15 AM · GlobeNewswire

EyePoint Announces Strategic Prioritization

Impact 3 · 7:00 AM · GlobeNewswire

EyePoint Announces Topline Results from LUCIA, the Second Pivotal Phase 3 Clinical Trial of DURAVYU™ in Wet AMD

15 Oct

Impact 3 · 10:04 AM · Zacks

Here's Why You Should Add EYPT Stock to Your Portfolio Now

18 Aug

Impact 5 · 12:32 AM

EyePoint (EYPT) Is Down 62.7% After DURAVYU Misses Phase 3 Endpoint In Wet AMD Trial – Has The Bull Case Changed?

Impact 4 · 11:09 AM

EyePoint Faces Regulatory Uncertainty After Lugano Trial Miss, RBC Capital Markets Says

Impact 4 · 10:40 AM · clinicaltrialsarena.com

EyePoint’s Duravyu falls short to Eylea in Phase III trial

Impact 4 · 7:57 AM · Stocktwits

EyePoint’s Regulatory Overhang May Take Time To Clear After Wet AMD Trial Setback, RBC Says – Retail Calls EYPT Slump A ‘Huge Overreaction’

Impact 4 · 2:12 AM

EyePoint (EYPT) LUGANO Data Resets The Story, Is It A Bargain?

17 Aug

Impact 5 · 9:37 AM

The Surprising Reason EyePoint Just Crashed 69%

Impact 4 · 7:51 PM · Stocktwits

OCUL, FDMT Stock Clock Best Day In Weeks After EyePoint’s Trial Setback — Here’s Why

Impact 4 · 1:09 PM

EyePoint Stock Craters 69% After Drug Trial Failure. It May Be an Overreaction.

Impact 4 · 12:02 PM · MarketBeat

EyePoint’s DURAVYU Misses Primary Endpoint in Phase III Wet AMD Trial

Impact 4 · 11:14 AM

EyePoint Stock Craters 71% After Drug Trial Failure. It May Be an Overreaction.

Impact 4 · 10:56 AM · InvestorsHub

EyePoint DURAVYU Phase 3 LUGANO Trial Misses Primary Endpoint as Secondary Data Show Reduced Treatment Burden

Impact 4 · 9:19 AM · Stocktwits

EYPT Stock On Track To Hit 16-Month Lows After Wet AMD Trial Setback – Retail Sees Ocular Therapeutics As A Better Buyout Candidate

Impact 4 · 7:00 AM

EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU™ 2.7mg in Wet AMD

5 Aug

Impact 4 · 7:00 AM

EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments

4 Aug

Impact 3 · 11:59 AM

Ocular Therapeutix's NDA Plans for Axpaxli in Wet AMD Remain on Track, RBC Says

30 Jul

Impact 4 · 7:00 AM

EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU™ for Treatment of Diabetic Macular Edema (DME)

29 Jul

Impact 3 · 10:00 AM

Earnings Preview: EyePoint (EYPT) Q2 Earnings Expected to Decline

26 May

Impact 4 · 12:04 PM · MarketBeat

EyePoint Pharmaceuticals Eyes Transformative 2026 as DURAVYU Phase 3 Data Nears

21 May

Impact 4 · 1:13 AM · Simply Wall St.

How The EyePoint (EYPT) Narrative Is Evolving With DURAVYU Trials And New Analyst Targets

14 May

Impact 4 · 7:00 AM · GlobeNewswire

EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence Ahead of Mid-2026 Topline Data

EyePoint, Inc.

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

EyePoint, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 27 April 2026

Chief executive’s pay

Ownership

EyePoint, Inc. (EYPT) Latest News

28 Oct

20 Oct

19 Oct

15 Oct

18 Aug

17 Aug

5 Aug

4 Aug

30 Jul

29 Jul

26 May

21 May

14 May

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

EyePoint, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 27 April 2026

Chief executive’s pay

Ownership

EyePoint, Inc. (EYPT) Latest News

28 Oct

20 Oct

19 Oct

15 Oct

18 Aug

17 Aug

5 Aug

4 Aug

30 Jul

29 Jul

26 May

21 May

14 May

Stockrow Weekly